Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Pfizer to Ship Half as Many Coronavirus Vaccine Doses as Originally Planned in Initial Phase

By Eric Volkman - Dec 3, 2020 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company puts the blame on difficulties with raw materials, among other challenges.

The supply of the coronavirus vaccine developed by Pfizer ( PFE 2.54% ) and BioNTech ( BNTX -2.97% ) will be significantly lower than first anticipated -- at least in the initial stages of distribution. Pfizer said that it will likely ship only half of the doses it originally planned, due to a set of challenges it wasn't able to surmount.

Addressing two of these, an unnamed company spokeswoman, quoted in The Wall Street Journal, said that "Scaling up the raw material supply chain took longer than expected, and it's important to highlight that the outcome of the clinical trial was somewhat later than the initial projection."

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

As a result, around 50 million doses of BNT162b2 will be shipped by the end of this year, down from the initial goal of 100 million. Next year, though, the big pharmaceutical company should be able to mobilize its supply and logistics efforts to distribute over 1 billion doses throughout the world.

BNT162b2 is administered in a two-dose regimen, with the booster shot coming several weeks after the first jab.

News about the supply shortfall comes one day after BNT162b2 received approval for emergency use by the U.K. government. The government said that the vaccine would start to be distributed and administered in the country next week.

BNT162b2, which showed an extremely high efficacy rate of 95% with no serious safety concerns in phase 3 clinical trials, has been submitted for similar approvals throughout the European Union, and with the U.S. Food and Drug Administration (FDA). In the wake of the U.K. approval, Pfizer and BioNTech anticipate decisions from other major regulators this month.

On Thursday, Pfizer's stock price fell harder than the S&P 500 index, declining by 1.7%.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$53.73 (2.54%) $1.33
BioNTech SE Stock Quote
BioNTech SE
$351.74 (-2.97%) $-10.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.